[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:diffuse-glioma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":42,"states":43},"Diffuse Glioma",5,[7,15,22,29,36],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05588141","A Phase I\u002FII Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.163159Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05580562","ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)",[19],"Phase 3","2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.610964Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT04099797","C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)",[26],"Phase 1","2026-08-26T02:16:22.235886Z","2026-05-05T02:43:27.089113Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":34,"content_modified":35},"NCT05717153","Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma",[33],"Early Phase 1","2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.732512Z",{"nct_id":37,"title":38,"phases":39,"status":12,"updated_at":40,"content_modified":41},"NCT05733312","Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption",[],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.392583Z",[],[44],{"state":45,"count":46,"slug":47},"Minnesota",3,"minnesota"]